Overall rank by patents
#24,393
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 2 technology areas, active 2022–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61B (DIAGNOSIS; SURGERY; IDENTIFICATION).
The verdict
GT holds 11 US patents across 2 technology areas, rank #24,393 of 50,000 tracked assignees.
GT Metabolic Solutions, Inc. has been granted 11 US utility patents between 2022 and 2025, placing GT Metabolic Solutions, Inc. at rank #24,393 across all assignees tracked by PlainPatent. This portfolio spans 2 distinct Cooperative Patent Classification (CPC) subclasses, averaging 23.3 claims per patent with primary concentration in A61B (DIAGNOSIS; SURGERY; IDENTIFICATION). As a US Corporation, GT Metabolic Solutions, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, GT sits between Groninger & Co. Gmbh (11 patents, rank #24,389) and Guangzhou Faner Aroma Product Co., Ltd. (11 patents, rank #24,397) - the closest US assignees by grant volume. The composite Innovation Score of 47.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2022 through 2025, with 11 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. GT Metabolic Solutions, Inc.'s 23.3 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 2 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark GT Metabolic Solutions, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
GRONINGER & CO. GMBH
11 patents
GS Elektromedizinische Geräte G. Stemple GmbH
11 patents
GSC SECRYPT, LLC
11 patents
GSK Consumer Healthcare SARL
11 patents
GUANGDONG HUARUN PAINTS CO., LTD
11 patents
GUANGDONG UNILUMIN ENERGY SAVING TECHNOLOGY CO., LTD
11 patents
GUANGZHOU CONSTRUCTION ENGINEERING CO., LTD.
11 patents
GUANGZHOU FANER AROMA PRODUCT CO., LTD.
11 patents
GT METABOLIC SOLUTIONS, INC.
11 patents
What this shows GT holds 11 patents at rank #24,393, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
GT's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
48 Top 18% higher than 82% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 2 | 18.2% |
| 2023 | 5 | 45.5% |
| 2025 | 4 | 36.4% |
Top 2 of 2 technology areas
Overall rank by patents
#24,393
Across all tracked assignees
47.5 out of 100
How to use this portfolio
GT's 11 grants land it in the top 18% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.